ICM EVIDENCE FOR AF MANAGEMENT
Studies of insertable cardiac monitor use in atrial fibrillation management
You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic does not review or control the content on the other website, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in the United Kingdom.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Studies of insertable cardiac monitor use in atrial fibrillation management
Reveal™ ICM Detects AF Burden Correctly 98% of the Time1
Relevance of Asymptomatic Arrhythmia Recurrence2
Prospective study of 114 AF-ablation patients followed by 7-day Holter before ablation, right after ablation, and after 3, 6, and 12 months of follow-up.
“Even in patients presenting with highly symptomatic AF, asymptomatic episodes may occur and significantly increase after catheter ablation. A symptom-only-based follow-up would substantially overestimate the success rate.”
More Patients Properly Detected and More Decisions Made with Reveal ICM3
More patients discontinue AADs with Reveal™ insertable cardiac monitoring
Majority of Patients Had NOAF; ILR Needed to Detect AF4